{"nctId":"NCT00449930","briefTitle":"Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)","startDateStruct":{"date":"2007-03-01","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":1050,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: sitagliptin phosphate"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Comparator: metformin hydrochloride"]}],"interventions":[{"name":"sitagliptin phosphate","otherNames":["MK0431"]},{"name":"Comparator: metformin hydrochloride","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"General Inclusion Criteria:\n\n* Patient has type 2 diabetes mellitus (T2DM)\n* Patient is inadequately controlled and not on treatment with insulin or oral antihyperglycemic therapy\n\nGeneral Exclusion Criteria:\n\n* Patient has a history of type 1 diabetes mellitus or history of ketoacidosis\n* Patient was on antihyperglycemic therapy (insulin or oral) within the prior 4 months","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"78 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24","description":"HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the Week 0 HbA1c percent.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.43","spread":null},{"groupId":"OG001","value":"-0.57","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Diarrhea","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"509","spread":null},{"groupId":"OG001","value":"465","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Nausea","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"522","spread":null},{"groupId":"OG001","value":"506","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Abdominal Pain","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"517","spread":null},{"groupId":"OG001","value":"502","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Vomiting","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"526","spread":null},{"groupId":"OG001","value":"515","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10},"commonTop":["Any Gastrointestinal disorders","Diarrhoea"]}}}